2025. Trial in Progress: A Phase 3 Randomized Study of Low-Dose Intralesional Cemiplimab Versus Primary Surgery for Patients With Early-Stage Cutaneous Squamous Cell Carcinoma (CLEAR CSCC). SKIN The Journal of Cutaneous Medicine. 9, 6 (Nov. 2025), s689. DOI:https://doi.org/10.25251/cpgrax68.